Close

Anna Vassall

PhD

Professor
of Health Economics

LSHTM
15-17 Tavistock Place
London
WC1H 9SH
United Kingdom

Tel.
++442079272141

I am a health economist with over twenty five years of experience in economic analysis and research in low and middle income countries. I have extensive experience supporting national health planning and priority setting, aid effectiveness, and cost-effectiveness analysis in a wide range of low and middle income countries. I have directed and provided economic support to European Community and World Bank funded health sector reform and development projects in Yemen, East Timor, Syria and Sudan: supporting the development of health benefit package, national strategic plans and medium term expendtiure frameworks. 

I am currently the Director of the Centre for Health Economics in London (CHiL) and sits in the Department of Global Health at LSHTM. I have led a wide range of influential economic analyses on HIV prevention for key populations (Avahan programme), the integration and organisation of HIV care and treatment services (Integra project), and new diagnostics  for TB (Xpert MTB/RIF) and the prevention of violence against women and girls (What Works). I have an interest in methods to incorporate health systems and other constraints and a societal/equity focussed perspective into economic evaluation and priority setting. I am the module organiser for LSHTM's distance learning course in economic evaluation. 

I am a founding member of the TB-MAC modelling consortium and sit on the technical advisory group for health technology assessment at WHO. I sat on the Strategic and Technical Advisory Group for the WHO's Global TB Programme (STAG-TB) and Task Force on Catastrophic Cost Measurement for TB, and on the Lancet Commission for TB. I was a lead investigator of the Global Health Costing Consortium; a Bill and Melinda Gates funded project to estimate and analyse HIV, TB and other health service costs globally. I am  currently supporting several countries develop health benefit packages as part of the Disease Control Priorities (DCP) project. I was awarded the Joep Lange Chair at the Amsterdam Institute for Global Health, University of Amsterdam in 2018.

 

Affiliations

Faculty of Public Health and Policy
Department of Global Health and Development

Centres

TB Centre

Teaching

Anna is the module organiser for the economic evaluation distance learning course at LSHTM

Research

Anna's current research interests include: defining health benefit packages and priority setting; the economic evaluation of infectious disease interventions; costing global health interventions; and, the economics of the prevention of violence against woman and girls. She is developing methods for: the economic evaluation of intersectoral interventions; the inclusion of patient, community societal costs in economic evaluation; and, the economic evaluation of health systems interventions. She has a keen interest in 'real world' evaluation methods. She also continuees to publish on health financing, in particular the role of development assistance for health, and fiscal space analyses. 

Research Area
Complex interventions
Decision analysis
Diagnostics
Economic evaluation
Health care financing
Health systems
Health technology assessment
Infectious disease policy
Research : policy relationship
Sexual health
Equity
Global Health
Reproductive health
Modelling
Discipline
Development studies
Economics
Disease and Health Conditions
HIV/AIDS
Mental health
Tuberculosis
Non-communicable diseases
Sexually transmitted infection
Country
Bangladesh
Bolivia
Brazil
China
Egypt
Ethiopia
Georgia
Ghana
India
Kenya
Mozambique
Malawi
Nepal
Pakistan
Peru
Sudan
South Sudan
Swaziland
Timor-Leste
Tanzania
Uganda
Ukraine
Vietnam
Yemen
South Africa
Zambia
Region
Arab World
East Asia & Pacific (developing only)
Europe & Central Asia (developing only)
Least developed countries: UN classification
Middle East & North Africa (developing only)
Pacific island small states
South Asia
Sub-Saharan Africa (developing only)

Selected Publications

Investing in the health of girls and women: a best buy for sustainable development.
Remme M; Vassall A; Fernando G; Bloom DE
2020
BMJ (Clinical research ed.)
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M; Centre for the Mathematical Modelling of Infectious Diseases COV
2020
medRxiv preprint
Reference case for estimating the costs of global health services and Interventions
Vassall A; Sweeney S; Kahn J; Gomez Guillen G; Bollinger L; Marseille E; Herzel B; DeCormier Plosky W; Cunnama L; Sinanovic E
2018
When an emerging disease becomes endemic.
Medley GF; Vassall A
2017
Science (New York, NY)
Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation.
Vassall A; Siapka M; Foster N; Cunnama L; Ramma L; Fielding K; McCarthy K; Churchyard G; Grant A; Sinanovic E
2017
The Lancet Global health
Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study.
Verguet S; Riumallo-Herl C; Gomez GB; Menzies NA; Houben RMGJ; Sumner T; Lalli M; White RG; Salomon JA; Cohen T
2017
The Lancet Global health
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models.
Menzies NA; Gomez GB; Bozzani F; Chatterjee S; Foster N; Baena IG; Laurence YV; Qiang S; Siroka A; Sweeney S
2016
The Lancet Global health
Incorporating Demand and Supply Constraints into Economic Evaluations in Low-Income and Middle-Income Countries.
Vassall A; Mangham-Jefferies L; Gomez GB; Pitt C; Foster N
2016
Health economics
Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India.
Vassall A; Pickles M; Chandrashekar S; Boily M-C; Shetty G; Guinness L; Lowndes CM; Bradley J; Moses S; Alary M
2014
The Lancet Global health
Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT
2011
PLoS medicine
See more Publications